



## Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5

February 25, 2019

BOSTON, Feb. 25, 2019 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](http://www.ziopharm.com), Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended Dec. 31, 2018.

The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 3091306. To access the slides and live webcast or the subsequent archived recording, visit the "Investors & Media" section of the Ziopharm website at [www.ziopharm.com](http://www.ziopharm.com). The webcast will be recorded and available for replay on the Company's website for two weeks.

### About Ziopharm Oncology, Inc.

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral *Sleeping Beauty* platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The *Sleeping Beauty* platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's very rapid T-cell manufacturing process. The *Sleeping Beauty* platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform or Ad-RTS-hIL-12 plus vedimex as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

### Company contacts:

David Connolly  
Vice President, Corporate Communications and Investor Relations  
617-502-1881  
[dconnolly@ziopharm.com](mailto:dconnolly@ziopharm.com)

Mike Moyer  
Vice President, Portfolio Strategy  
617-765-3770  
[mmoyer@ziopharm.com](mailto:mmoyer@ziopharm.com)



Source: ZIOPHARM Oncology Inc